Seamless Therapeutics and Eli Lilly have entered a global collaboration to develop programmable recombinase-based gene editing therapies for genetic hearing loss, with Seamless eligible for over $1.12 billion in milestone payments plus royalties.
Written By: Pharmacally Medical News Desk
Seamless Therapeutics has announced a strategic global research collaboration and licensing agreement with Eli Lilly and Company to develop and commercialize new gene-editing therapies for genetic hearing loss. The partnership will focus on programmable recombinase-based treatments, leveraging Seamless’ proprietary technology platform designed for large, precise DNA insertions.
The collaboration aims to address mutations in specific genes linked to hearing loss, an area where patients currently have limited disease-modifying options.
Programmable Recombinases as a Novel Gene Editing Approach
Unlike many traditional gene-editing methods that rely on the cell’s natural DNA repair pathways, Seamless’ recombinase platform enables precise DNA insertions independent of these mechanisms. This approach may allow for more controlled and predictable genetic corrections.
Seamless will be responsible for designing and programming site-specific recombinases capable of correcting mutations in selected hearing-loss-related genes. Lilly will receive an exclusive license to advance these engineered recombinases through preclinical development, clinical trials, and potential commercialization.
Leadership Highlights the Potential for Genetic Hearing Loss
Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics, said the partnership reflects a shared commitment to advancing genetic medicines for patients with unmet needs.
He noted that Lilly’s investment in novel treatment strategies for genetic disease validates Seamless’ platform and supports the broader therapeutic potential of programmable recombinases.
Financial Terms and Milestone Opportunity
Under the agreement, Seamless will receive an upfront payment along with committed research and development funding. The company is eligible for more than $1.12 billion in total payments, including development and commercial milestone achievements. Additional tiered royalties may also be paid on any successfully marketed therapies. Specific financial details beyond these headline terms have not been disclosed.
Expanding the Therapeutic Reach of Recombinase Gene Editing
Recombinases have been widely used in scientific research for decades, but Seamless is working to translate major advances in their programmability, accuracy, and genome-targeting flexibility into therapeutic applications.
The company’s platform enables engineered recombinases to precisely insert, exchange, invert, or excise DNA fragments within virtually any target gene sequence. This capability could open new possibilities for treating disorders caused by large or complex genetic mutations.
Outlook for Genetic Hearing Loss Innovation
With this partnership, Seamless and Lilly aim to develop potentially disease-modifying treatments for genetic hearing loss, an area of high unmet medical need. The agreement also strengthens the broader role of programmable recombinases as a next-generation gene-editing modality.
Reference
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss, 28 January 2026, https://seamlesstx.com/wp-content/uploads/2026/01/20260128_Final-Deal-PR-Lilly_Final_Website.pdf